EP396 Five-year survival and prognostic factors in women treated for cervix cancer at a tertiary care center. (1st November 2019)

• Record Type: Journal Article
• Authors: Sait, K; Anfinan, N; Sait, H
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 4
• Page Start: A263
• Page End: A263
• Publication Date: 2019-11-01
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-ESGO.455
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: It is crucial to investigate survival in cervix cancer at the local level to provide an approach on the effectiveness of the overall management, as it reflects the level of care of the patients and the awareness among the population about screening and early diagnosis. Thus, this we conducted this study to provide insight into the medium term prognosis of treated cervix cancer by estimating the 5-year survival rate and investigating the associated clinical, management- and outcome-related factors and predictors. Methodology: A retrospective study including women with cervix cancer who were treated at the Gynecology Oncology Unit in King Abdulaziz University Hospital, Jeddah, and who achieved at least 60 months (5 years) of follow up. Baseline demographic and clinical data, tumor characteristics, treatment option and outcome including recurrence were collected and analyzed as factors of 5-year survival. Results: A total 153 patients were included, mean (SD) age was 54.52 (13.47) years. Tumor characteristics showed FIGO stage (I [19.6%], II [50.3%], III [15.7%], IV [14.4%]), (grade I [17.6%], grade II [46.4%], grade III [35.3%]) and the most frequent histological type was squamous cell carcinoma (73.9%). Patients received initial radiotherapy with concurrent chemotherapy (51.6%), systemic CT (3.9%) and palliative care (5.9%). The 5-year survival rate (95% CI) was 51.6% (43.4%, 59.8%), which was independently predicted by tumor grade II (OR=0.08, p=0.009), grade III (OR=0.05, p=0.004) and recurrence (OR=0.09, p<0.001). Conclusion: 5-year survival figures are relatively lower than in developed countries but better than in other developing countries. Remarkably, this study evidenced a high percentage of patients diagnosed at advanced-stage, which probably impacts survival and stresses the need of improving early detection. Disclosure: Nothing to disclose.